Text me. I’d love to hear from you! Can you relate to anything we said? What do want to hear more about?

In this powerful episode, tumor immunologist Dr. Mike Olin  and pediatric neuro-oncologist Dr. Chris Moertel share how a University of Minnesota discovery, centered on the immune-silencing molecule CD200, sparked a revolutionary clinical trial for one of the deadliest childhood brain cancers.

They reveal what it took to get the drug into children, the upcoming Phase 2 trial, and exactly why donor support is the only thing that moves this work forward.

In this episode, you’ll learn:

• The discovery that changed everything: Blocking CD200 so the immune system can finally recognize the tumor.
• From idea to children: Adult testing ➜ FDA approval ➜ pediatric Phase 1 trial now underway.
• The next critical step: A multi-site Phase 2 trial led by PI Dr. Anne Bendel, designed to prove efficacy and unlock fast-track access for kids.
• A smarter, more affordable approach: Focused ultrasound that replaces costly tumor-lysate vaccines and boosts survival in early models.
• Why funding is urgent: Drug manufacturing, MRI imaging, lab testing, regulatory oversight, and even travel and lodging for families—all dependent on donations.
• The broader impact: This discovery may also help patients with breast-to-brain metastases and other CD200-positive tumors.

Why your donation matters:

Every dollar directly accelerates:

• More kids enrolled in trials
• More drug manufactured and delivered
• More MRIs, labs, and safety testing completed
• More families able to travel for treatment
• Faster progress toward FDA fast-track approval

Every contribution moves a child closer to treatment. 

Support Sally’s mission to raise $1 million for medical research and help bring life-saving treatment to children who need it now.

Donate at unstoppablestoriesthatmove.com